# FDA recall D-1312-2014

> **Merck & Co Inc** · Class III · drug recall initiated 2014-01-13.

## Product

Liptruzet (ezetimibe and atorvastin) tablets,10 mg/80 mg, a) 30 count blister    (NDC 66582-323-30), b) 90 count blister  (NDC 66582-323-54), Rx only, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc, Whitehouse Station, NJ 08889

## Reason for recall

Defective Container; some of the outer laminate foil pouches allowed in air and moisture, which could potentially decrease the effectiveness or change the characteristics of the product.

## Distribution

Nationwide and Puerto Rico

## Key facts

- **Recall number:** D-1312-2014
- **Recalling firm:** Merck & Co Inc
- **Classification:** Class III
- **Product type:** drug
- **Status:** Terminated
- **Initiation date:** 2014-01-13
- **Report date:** 2014-05-14
- **Termination date:** 2015-09-02

- **Voluntary/Mandated:** Voluntary: Firm initiated
- **Location:** Whitehouse Station, NJ, United States

## Primary source

FDA Enforcement Reports: https://www.accessdata.fda.gov/scripts/ires/index.cfm?Product=D-1312-2014

## Citation

> AI Analytics. FDA recall D-1312-2014. Retrieved 2026-06-13 from https://api.ai-analytics.org/recall/D-1312-2014. Source: US FDA. Licensed CC0.

---

*[Dataset catalog](/datasets/) · [FDA recalls dataset](/datasets/fda-recalls) · CC0 1.0*